Children's Hospital of Philadelphia Purchases Large-Scale Illumina(R) System to Genotype Children, Study Childhood Disease and Guide Therapy
Wednesday June 7, 6:00 am ET
New Facility Provides Model for the Routine Integration of Genotyping and Personalized Medicine into the Clinic
SAN DIEGO--(BUSINESS WIRE)--June 7, 2006--Illumina, Inc. (NASDAQ:ILMN - News) announced today an agreement with The Children's Hospital of Philadelphia for the purchase of a large-scale system capable of producing 150 million genotypes per day. The Illumina system will be housed at the hospital's new Center for Applied Genomics and will provide a core capability for the Center's unprecedented research goal of ultimately genotyping over 100,000 children. The knowledge gained from these studies is expected to provide significant insight into the genetic basis of common childhood disease, linking genetic variations called SNPs (single nucleotide polymorphisms) with specific illnesses. The results will guide therapy and drive development of new treatments. Including arrays and reagents for the first 30,000 samples, the initial value of the agreement is expected to exceed $25 million.
ADVERTISEMENT
The Center for Applied Genomics will focus on some of the most prevalent diseases of childhood -- asthma, obesity, diabetes and cancer among others -- all of which are thought to involve the contributions of multiple, interacting genes. The Center's researchers will then work to translate the genetic knowledge into precisely targeted treatments for the diseases in question, customizing treatments to a child's genetic profile.
The genotyping studies will be guided by Hakon Hakonarson, M.D., Ph.D., a Director at the Center. In addition to mapping gene variants to disease risk, Dr. Hakonarson and colleagues plan to investigate how genes interact with environmental factors.
"We will be tracing the major underlying genetic component of disease-related genes while discovering the biological pathways involved in disease development," Dr. Hakonarson explained. "For instance, a specific cholesterol receptor may be dysregulated because of genetics, or the pathway may also be dysregulated because of an unhealthy diet. If we can identify key bottlenecks for dysregulation, we may able to treat not only the five percent of people with a particular gene variant for a disease, but also the larger percentage who suffer the disease without having that variant."
The ultimate aim of the Center's investigators is to enable tailoring of treatments to patients' individual profiles, formally introducing into the clinic a personalized approach to medicine with the intent of improving outcomes while creating a new model for clinical practice around the world.
"We are following a trail blazed by the Human Genome and HapMap Projects, but tailoring our approach to children," said Philip R. Johnson, M.D., chief scientific officer at The Children's Hospital of Philadelphia. "As one of the world's largest and most comprehensive pediatric networks, we have a sizable base of patients and families from which to collect data. This focused effort in genomics reaffirms that we are absolutely committed to finding cures for childhood diseases."
When installed, the system will be capable of producing 150 million genotypes per day, all extracted from blood samples. To accommodate its ambitious sample analysis objectives, patients at Children's Hospital and throughout its network of pediatricians' offices and satellite centers will be asked to contribute blood samples. For those who agree, a sophisticated information management system will track the samples and store medical records information in an encrypted form to preserve patient confidentiality. Clinicians will also ask the children's parents to contribute blood samples and divulge medical information to further strengthen the project's base of information.
"Our sample size will be large enough to provide great statistical power to our research," added Dr. Hakonarson. "We will be able to characterize genotypes and health conditions over a sizable population of children. This project will help to set the standard for identifying biological links to childhood diseases."
Dr. Hakonarson and his colleagues will first conduct whole-genome genotyping using Sentrix® HumanHap550 BeadChips, each of which can analyze over 550,000 single nucleotide polymorphism (SNP) loci with industry-leading per-sample genomic coverage and data quality. Subsequent phases will use Illumina arrays and reagents to study focused sets of SNPs thought to be implicated in disease cause and progression.
While focused initially on SNP genotyping, the Center's research teams expect to use the BeadLab for a range of integrated genetic studies, including but not limited to whole-genome and focused gene expression to characterize certain diseases and analyze biological pathways, discover and validate disease-related biomarkers, and understand interactions between human genes and environmental exposures.
The system installation will be centered around Illumina's BeadLab with a substantial number of additional scanner and automation components. The BeadLab is an end-to-end genetic analysis solution built around Illumina's proprietary BeadArray(TM) technology and featuring extensive automation, parallel sample throughput, multiplexed assay protocols, a laboratory information management system (LIMS) for positive sample tracking, low running cost per sample and industry-leading performance. The system leverages Illumina's powerful assay technologies including Infinium(TM) and GoldenGate® genotyping and the DASL(TM) assay for profiling gene expression of degraded RNAs.
"The whole-genome genotyping market continues to grow rapidly as investigators design exciting studies and build capacity to generate and analyze the genetic information necessary to help understand the molecular basis of disease," stated Jay Flatley, Illumina President and CEO. "The Center for Applied Genomics will benefit from a facility that is unrivaled in the world of disease research. We're gratified to be able to contribute so meaningfully to the Hospital's exciting research agenda with our flagship HumanHap550 product. More broadly, our agreement with Children's Hospital is another dramatic step in the evolution of the genotyping market, setting the stage for what we believe will be routine application in the fast-emerging field of predictive diagnostics."
About Children's Hospital
The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit chop.edu.
About Illumina
Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. |
